title: Increased levels of circulating platelet-derived microparticles are associated with metastatic cutaneous melanoma.
abstract: We investigated the plasma levels of PMPs in patients with 45 stage III and 45 stage IV melanoma. PMPs were characterised by flow cytometry and their thrombogenic activity. We also investigated the link between PMPs circulating levels and tumor burden. The circulating levels of PMPs were significantly higher in stage IV (8500 μL-1) than in patients with stage III (2041 μL-1) melanoma (P=.0001). We calculated a highly specific (93.3%) and predictive (91.7%) cut-off value (5311 μL-1) allowing the distinction between high-risk stage III and metastatic stage IV melanoma. The thrombogenic activity of PMPs was significantly higher in patients with stage IV melanoma (clotting time: 40.7 second vs 65 second, P=.0001). There was no significant association between the radiological tumoral syndrome and the plasma level of PMPs. Our data suggest the role of PMPs in metastatic progression of melanoma.
authors.affiliation: INSERM UMR 1098, University of Bourgogne Franche Comté, Besançon, France.|Department of Dermatology, University Hospital, Besançon, France.
authors.forename: Joséphine
authors.initials: J
authors.lastname: Moreau
authors.affiliation: INSERM UMR 1098, University of Bourgogne Franche Comté, Besançon, France.|Department of Dermatology, University Hospital, Besançon, France.
authors.forename: Fabien
authors.initials: F
authors.lastname: Pelletier
authors.affiliation: INSERM UMR 1098, University of Bourgogne Franche Comté, Besançon, France.|Etablissement Français du Sang Bourgogne Franche Comte, Besançon, France.
authors.forename: Sabeha
authors.initials: S
authors.lastname: Biichle
authors.affiliation: INSERM UMR 1098, University of Bourgogne Franche Comté, Besançon, France.|Etablissement Français du Sang Bourgogne Franche Comte, Besançon, France.
authors.forename: Guillaume
authors.initials: G
authors.lastname: Mourey
authors.affiliation: Clinical Methodology Center, Besançon University Hospital, Besançon, France.
authors.forename: Marc
authors.initials: M
authors.lastname: Puyraveau
authors.affiliation: Department of Radiology, Besançon University Hospital, Besançon, France.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Badet
authors.affiliation: Department of Radiotherapy, Besançon University Hospital, Besançon, France.
authors.forename: Matthieu
authors.initials: M
authors.lastname: Caubet
authors.affiliation: Department of Dermatology, University Hospital, Besançon, France.
authors.forename: Claire
authors.initials: C
authors.lastname: Laresche
authors.affiliation: INSERM UMR 1098, University of Bourgogne Franche Comté, Besançon, France.|Etablissement Français du Sang Bourgogne Franche Comte, Besançon, France.
authors.forename: Francine
authors.initials: F
authors.lastname: Garnache-Ottou
authors.affiliation: INSERM UMR 1098, University of Bourgogne Franche Comté, Besançon, France.|Etablissement Français du Sang Bourgogne Franche Comte, Besançon, France.
authors.forename: Philippe
authors.initials: P
authors.lastname: Saas
authors.affiliation: INSERM UMR 1098, University of Bourgogne Franche Comté, Besançon, France.|Etablissement Français du Sang Bourgogne Franche Comte, Besançon, France.
authors.forename: Estelle
authors.initials: E
authors.lastname: Seilles
authors.affiliation: INSERM UMR 1098, University of Bourgogne Franche Comté, Besançon, France.|EA3181, University of Bourgogne Franche Comté, Besançon, France.
authors.forename: François
authors.identifier: 0000-0002-1421-4996
authors.initials: F
authors.lastname: Aubin
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood; D001777:Blood Coagulation; D001792:Blood Platelets; D055252:Cell-Derived Microparticles; D006801:Humans; D008545:Melanoma / Q000097:blood* / Q000556:secondary; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D012878:Skin Neoplasms / Q000097:blood* / Q000473:pathology; D047368:Tumor Burden
chemical_list: D014408:Biomarkers, Tumor
keywords: melanoma; platelet-derived microparticles; platelets; thrombogenic activity; tumor burden